ES2128846T3 - Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales. - Google Patents

Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.

Info

Publication number
ES2128846T3
ES2128846T3 ES96909200T ES96909200T ES2128846T3 ES 2128846 T3 ES2128846 T3 ES 2128846T3 ES 96909200 T ES96909200 T ES 96909200T ES 96909200 T ES96909200 T ES 96909200T ES 2128846 T3 ES2128846 T3 ES 2128846T3
Authority
ES
Spain
Prior art keywords
fumagilol
derivatives
intestinal infections
sub
drugs intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909200T
Other languages
English (en)
Inventor
Jean-Michel Molina
Francis Derouin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Sanofi SA
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Assistance Publique Hopitaux de Paris APHP filed Critical Sanofi SA
Application granted granted Critical
Publication of ES2128846T3 publication Critical patent/ES2128846T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE FUMAGILOL Y ESTERES FORMADOS POR FUMAGILOL Y ACIDOS (C{SUB,1} C{SUB,12})ALQUILCARBOXILICOS O (C{SUB,1} C{SUB,12})ALQUILDICARBOXILICOS, SATURADOS O INSATURADOS, Y DE SUS SALES FARMACEUTICAMENTE ACEPTABLES PARA LA PREPARACION DE MEDICAMENTOS DESTINADOS A COMBATIR INFECCIONES INTESTINALES DEBIDAS A MICROSPORIDIOS Y CRIPTOSPORIDIOS.
ES96909200T 1995-03-27 1996-03-26 Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales. Expired - Lifetime ES2128846T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27

Publications (1)

Publication Number Publication Date
ES2128846T3 true ES2128846T3 (es) 1999-05-16

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909200T Expired - Lifetime ES2128846T3 (es) 1995-03-27 1996-03-26 Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.

Country Status (25)

Country Link
US (1) US5900431A (es)
EP (1) EP0817626B1 (es)
JP (1) JP3260378B2 (es)
KR (1) KR100286920B1 (es)
CN (1) CN1072485C (es)
AP (1) AP646A (es)
AT (1) ATE172641T1 (es)
AU (1) AU706161B2 (es)
CA (1) CA2216623C (es)
CZ (1) CZ286821B6 (es)
DE (1) DE69600879T2 (es)
DK (1) DK0817626T3 (es)
EA (1) EA000150B1 (es)
ES (1) ES2128846T3 (es)
FR (1) FR06C0014I2 (es)
HU (1) HU224028B1 (es)
IS (1) IS2048B (es)
NO (1) NO315968B1 (es)
NZ (1) NZ304906A (es)
OA (1) OA10515A (es)
PL (1) PL183378B1 (es)
SK (1) SK283883B6 (es)
TR (1) TR199701048T1 (es)
UA (1) UA41446C2 (es)
WO (1) WO1996030010A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
DE60034770T2 (de) 1999-02-26 2008-04-30 Sanofi-Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
MX2010005857A (es) * 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
EP2317845A4 (en) * 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
MX343135B (es) 2010-01-08 2016-10-25 Zafgen Corp * Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
CA2817199C (en) 2010-11-09 2019-01-15 Zafgen, Inc. Crystalline solids of a metap-2 inhibitor and methods of making and using same
EP2646016B1 (en) 2010-11-29 2017-05-17 Zafgen, Inc. Treatment if obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol
JP6058557B2 (ja) 2011-01-26 2017-01-11 ザフゲン，インコーポレイテッド テトラゾール化合物ならびにその作製方法および使用方法
EP2683706B1 (en) 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
CN104169268A (zh) 2012-01-18 2014-11-26 扎夫根股份有限公司 三环砜化合物及其制备和使用方法
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2013169727A1 (en) 2012-05-07 2013-11-14 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
JP2015516426A (ja) 2012-05-08 2015-06-11 ザフゲン，インコーポレイテッド ＭｅｔＡＰ２阻害剤による視床下部性肥満症の治療
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
WO2014152861A2 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
EA199700267A1 (ru) 1998-04-30
CZ304997A3 (en) 1997-12-17
DE69600879T2 (de) 1999-06-02
JPH11506421A (ja) 1999-06-08
NO974466L (no) 1997-09-26
AP646A (en) 1998-04-27
NO974466D0 (no) 1997-09-26
NZ304906A (en) 1999-06-29
IS4557A (is) 1997-09-11
AP9701092A0 (en) 1997-10-31
EP0817626A2 (fr) 1998-01-14
TR199701048T1 (xx) 1998-01-21
AU706161B2 (en) 1999-06-10
CN1072485C (zh) 2001-10-10
OA10515A (fr) 2002-04-24
WO1996030010A2 (fr) 1996-10-03
UA41446C2 (uk) 2001-09-17
EA000150B1 (ru) 1998-10-29
AU5278696A (en) 1996-10-16
KR19980703271A (ko) 1998-10-15
IS2048B (is) 2005-09-15
HUP9801220A2 (hu) 1999-09-28
SK283883B6 (sk) 2004-04-06
PL183378B1 (pl) 2002-06-28
DE69600879D1 (de) 1998-12-03
CZ286821B6 (en) 2000-07-12
HUP9801220A3 (en) 2001-10-29
PL322470A1 (en) 1998-02-02
SK130797A3 (en) 1998-03-04
FR06C0014I1 (es) 2006-11-17
FR06C0014I2 (es) 2006-12-29
WO1996030010A3 (fr) 1996-11-28
MX9707150A (es) 1998-07-31
US5900431A (en) 1999-05-04
HU224028B1 (hu) 2005-05-30
ATE172641T1 (de) 1998-11-15
CA2216623A1 (en) 1996-10-03
CN1179715A (zh) 1998-04-22
EP0817626B1 (fr) 1998-10-28
DK0817626T3 (da) 1999-07-12
JP3260378B2 (ja) 2002-02-25
CA2216623C (en) 2005-05-31
NO315968B1 (no) 2003-11-24
KR100286920B1 (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
ES2128846T3 (es) Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
AR034691A1 (es) Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende
AR005458A1 (es) 2-oxo-y 2-tio-1,2-dihidroquinolinil-oxazolidinonas, procedimiento para su produccion, el uso de las mismas para la produccion de un medicamento ymedicamentos que los contienen
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
UY26782A1 (es) Derivados del benzotiazol
ES2161290T3 (es) Derivados de quinazolina.
MX9305566A (es) Derivados de urea ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
HN2003000215A (es) Nuevos derivados de glicocido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos.
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2076226T3 (es) Utilizacion de trifluorometilfeniltetrahidropiridinas para la preparacion de medicamentos destinados para combatir las alteraciones ansio-depresivas.
CO4970795A1 (es) Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
KR890005088A (ko) 4- 아미노피리딘 유도체 및 그의 산 부가염
MX9302459A (es) Derivados imino ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
TR199801082T2 (xx) Fosfonokarbiksilik asitlerin yeni fosfolipid t�revleri, bunlar�n �retimi, bunun yan�s�ra bunlar�n antiviral farmas�tik maddeler olarak kullan�m�.
ES2074721T3 (es) Derivados de ciclopentano, procedimientos para su preparacion y su utilizacion farmaceutica.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR004503A1 (es) Uso de l-carnitina, l-carnitinas acilicas en las cuales el gruo acilo, lineal o ramificado, tiene entre 2 y 6 atomos de carbono y sus salesfarmaceuticamente aceptables, y composiciones farmaceuticas que comprenden tales compuestos
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 817626

Country of ref document: ES